HAHalozyme Therapeutics HALO · NASDAQ
$122.50 +0.54% (+$0.66)
- Market cap
- $13.8B
- Enterprise value
- $15.8B
- P/E
- 33.4x
- Forward P/E
- 12.9x
- PEG
- -
- P/S
- 8.3x
- P/FCF
- 17.2x
- EV/EBITDA
- 22.1x
- ROIC
- 27.4%
- Bruto marža
- 78.2%
- Neto marža
- 24.9%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- 2.8x
- Beta
- 0.88
- Free float
- 98.9%
O podjetju
Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing innovative therapeutic agents and technologies that improve drug absorption. Founded in 1998 and headquartered in San Diego, California, Halozyme is best known for its Enhanze™ platform, which uses enzymes to accelerate the absorption of biologic drugs, enabling them to be administered in lower doses or over shorter periods. The company collaborates with numerous pharmaceutical and biotechnology firms to develop new therapeutic products.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen I. Torley
Employees
423
Headquarters
San Diego
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke